Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flebogamma 5% DIF in Post-Polio Syndrome
NCT02176863Phase 3Terminated
- Sponsor
- Grifols
- Start
- Sep 2014
- Primary completion
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of gamunex in post-polio syndrome (PPS) (5 arms), sponsored by Grifols. Primary endpoint: Two-Minute Walk Distance at 52 weeks. Started Sep 2014; status: terminated.
02
Drugs
gamunex
03
Conditions
post-polio syndrome (PPS)
Beyond the preview
Go deeper on NCT02176863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02176863.